Application 074619
- Type
- ANDA
- Sponsor
- BARR LABS INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | GLIPIZIDE | GLIPIZIDE | TABLET;ORAL | 5MG | No | No |
| 002 | GLIPIZIDE | GLIPIZIDE | TABLET;ORAL | 10MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A074619-001 | GLIPIZIDE | GLIPIZIDE | 5MG | TABLET / ORAL | 1997-04-04 | ||
| A074619-002 | GLIPIZIDE | GLIPIZIDE | 10MG | TABLET / ORAL | 1997-04-04 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A074619-001 | GLIPIZIDE | 5MG | TABLET / ORAL | 1997-04-04 | 3a93d1ddd44b… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A074619-002 | GLIPIZIDE | 10MG | TABLET / ORAL | 1997-04-04 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A074619-001 | GLIPIZIDE | 5MG | TABLET / ORAL | 1997-04-04 | f41ea6bd6efb… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A074619-002 | GLIPIZIDE | 10MG | TABLET / ORAL | 1997-04-04 | f41ea6bd6efb… | ||
| 2022-09-29 23:25 UTC | 2022-09 | A074619-001 | GLIPIZIDE | 5MG | TABLET / ORAL | 1997-04-04 | e64feba35796… | ||
| 2022-09-29 23:25 UTC | 2022-09 | A074619-002 | GLIPIZIDE | 10MG | TABLET / ORAL | 1997-04-04 | e64feba35796… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A074619-001 | GLIPIZIDE | 5MG | TABLET / ORAL | 1997-04-04 | cb3db0bc1861… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A074619-002 | GLIPIZIDE | 10MG | TABLET / ORAL | 1997-04-04 | cb3db0bc1861… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A074619-001 | GLIPIZIDE | 5MG | TABLET / ORAL | 1997-04-04 | a50c72e98297… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A074619-002 | GLIPIZIDE | 10MG | TABLET / ORAL | 1997-04-04 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Glipizide | GLIPIZIDE | A-S Medication Solutions | 726fd41e-7831-4f94-8b28-d139105aad68 | 2026-11-04 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | Bryant Ranch Prepack | a59e2aaf-692c-4696-817b-3fed7a9dc52c | 2026-11-04 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | A-S Medication Solutions | a38cfe61-4aa5-498c-bca5-03a8213303bb | 2026-10-14 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | A-S Medication Solutions | 16fb8bc7-1db1-477e-a201-b3b678b8a84c | 2026-10-13 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | AiPing Pharmaceutical, Inc. | ccfa5a38-3f90-48f4-b226-51e91497c06f | 2026-10-09 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | AiPing Pharmaceutical, Inc. | 2110a7ca-3c1f-4db4-9211-65546b74533c | 2026-10-09 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | A-S Medication Solutions | 41d4e09b-b90c-4243-acd8-f2e06ebf4089 | 2026-10-09 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | PD-Rx Pharmaceuticals, Inc. | 861609da-6f69-43cf-a6a3-9f45a1d9eb23 | 2026-10-02 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | PD-Rx Pharmaceuticals, Inc. | c38c3c72-0ef2-4c06-8c67-a3f428ad172b | 2026-10-02 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | NuCare Pharmaceuticals, Inc. | 5ce323e4-ea8c-22b5-e063-6294a90a15bf | 2026-10-02 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | A-S Medication Solutions | 04e18105-0bd2-4353-b7d2-a73749de32b8 | 2026-09-29 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | PD-Rx Pharmaceuticals, Inc. | d9b6464f-6fe6-446e-8150-d0c15c46fee8 | 2026-09-28 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | PD-Rx Pharmaceuticals, Inc. | 1b2e5656-9da9-4fab-bf01-ed75896b836a | 2026-09-23 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | REMEDYREPACK INC. | 212897cb-7de7-4711-aaf4-44234f950e9f | 2026-09-22 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | REMEDYREPACK INC. | 376ce3cf-4e1b-4b5f-b3e7-cc9fc4a5aeb4 | 2026-09-22 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | Oxford Pharmaceuticals, LLC | 87cd4930-ba68-4acf-bf74-619c477b557d | 2026-09-17 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | NuCare Pharmaceuticals,Inc. | 6282c653-9e9c-6810-e053-2991aa0a4a8e | 2026-09-14 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | Apotex Corp. | dcf426b8-bcdc-8214-a1b6-6388bd3399a0 | 2026-09-11 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | REMEDYREPACK INC. | 667dd68a-d3e7-4b50-bd0a-d17783a090d5 | 2026-08-27 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
| Glipizide | GLIPIZIDE | Bryant Ranch Prepack | 00729e82-150a-464a-abe7-a3319721fbdb | 2026-08-27 | Warnings, Adverse reactions | Glipizide GLIPIZIDE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.